[Formulation and antileukemic activity of quinolizidinylalkylaminic derivatives of naphthoquinone and anthraquinone].
By reacting three quinolizidinylalkylamines with 1,4-naphtoquinone, 2,3-dichloronaphto-1,4-quinone and 1-chloroanthraquinone nine compounds were obtained which are of interest as antitumoral, antiviral, antibacterial and antiparasitic agents. These compounds, so far, have been tested against lymphocytic leukemia P 388 in mice and found inactive.